Lifeforce Capital

VC San Francisco, United States · Founded 2015

Lifeforce Capital invests in software-first companies reshaping the status quo in healthcare's largest markets, focusing on techbio platforms and innovative care delivery models.

About Lifeforce Capital

Lifeforce Capital presents as an early-stage venture investor with a thesis tilt toward longevity, performance health, and consumer biology, though detailed public materials on fund size, stage discipline, and check sizes are limited. Founders should treat it as a small fund operating in the seed and pre-seed range, with checks plausibly in the $100k to $500k band and a clear preference for direct-to-consumer health, supplement and diagnostic platforms, and software wrapped around clinician oversight. Physician founders building longevity, hormone optimization, metabolic health, or consumer-facing precision wellness products are the natural fit; founders building hospital-sold enterprise software, payer infrastructure, or hard regulated devices should look at firms with deeper clinical operating networks. The thin public footprint means due diligence should run in both directions. Ask for a portfolio list, names of two recent founders for backchannel reference, and explicit clarity on reserves before signing a term sheet. Geography is most likely US-centric, with comfort investing in remote-first teams. The most efficient entry path is a warm introduction from an existing portfolio founder or from a longevity-clinic operator inside the firm’s network; LinkedIn outreach to a partner with a personalized note that demonstrates clinical fluency tends to work better than generic deck submissions. The right pitch leads with biomarker outcomes, retention math, and a credible regulatory posture, not unmodeled TAM.

Founder reviews

No founder reviews yet. Raised from this fund? Share your experience with other founders.

Healthcare AI tools backed by Lifeforce Capital

Tools made by companies in Lifeforce Capital's portfolio that we cover in the directory.

Eko Foundation Analysis Software with Transformers (EFAST)
Eko Health
Cardiology AI
EFAST by Eko Health is an advanced, FDA-cleared AI model that assists clinicians in identifying structural murmurs associated with heart disease and detecting atrial fibrillation, providing real-time, actionable cardiac insights during routine exams.
VISENSIA
OBS MEDICAL
Clinical Decision Support & Reference
Visensia by OBS Medical is an FDA-cleared AI-powered clinical decision support software that fuses multiple vital signs into a single Safety Index (VSI) to provide early warning of patient deterioration, enhancing patient safety and optimizing clinical workflow across hospitals, EMS, and home care.
Eko Low Ejection Fraction Tool (ELEFT)
Eko Health
Cardiology AI
The Eko Low Ejection Fraction Tool (ELEFT) is an FDA-cleared AI algorithm that integrates with Eko digital stethoscopes to aid clinicians in the early detection of low ejection fraction, a key indicator of heart failure, during routine physical exams.
Fathom Medical Coding Automation
Fathom
Medical Billing & RCM
Fathom is an autonomous medical coding platform that uses AI to automatically code charts directly to billing, aiming to reduce costs, increase accuracy, and mitigate audit risk for healthcare organizations. It supports a wide range of healthcare providers and payers with high automation rates and accuracy.

Portfolio companies in our directory

Other portfolio companies

Companies in Lifeforce Capital's portfolio not currently in our directory.

Team

John Noonan
Founder and General Partner
LinkedIn
Sander Duncan
General Partner

Pitch / review this investor

Have you raised from Lifeforce Capital? Founders only — share your honest experience (anonymous OK, moderated before publishing).

Share your experience
Last updated 2026-05-06. Sourced from this fund's published materials.
AI Tool Finder
AI-powered search. Results may not be comprehensive.